Actively Recruiting
Evaluation of 18F-N230A PETCT Imaging to Detect Nectin-4 in Patients with Renal Cell Carcinoma and Renal Pelvic Urothelial Carcinoma
Led by Peking University First Hospital · Updated on 2026-10-15
80
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Renal cell carcinoma and renal pelvic urothelial carcinoma are common cancers of the urinary system. Accurate differentiation between these tumor types before surgery is important for planning treatment, but traditional imaging methods have limitations in showing tumor biology. Researchers are evaluating a new PET imaging agent called 18F-N230A, which targets Nectin-4, a molecule highly expressed in several epithelial cancers including urothelial carcinoma. This study assesses the safety, distribution, and imaging features of 18F-N230A PETCT in patients with suspected or confirmed renal tumors. Participants will receive an intravenous injection of 18F-N230A followed by PETCT scanning. They will also undergo standard 18F-FDG PETCT imaging for comparison. Imaging results and quantitative measurements from both scans will be analyzed and compared. Surgical or biopsy pathology results will serve as the reference to evaluate how well 18F-N230A PETCT distinguishes renal cell carcinoma from renal pelvic urothelial carcinoma. During the study, participants will undergo PETCT imaging sessions and pathological examinations within two months. Researchers will measure diagnostic accuracy, sensitivity, specificity, and uptake values of lesions on PETCT images. These assessments aim to provide a new molecular imaging approach to improve diagnosis and support personalized treatment decisions for renal tumors. The total participation duration includes imaging and follow-up for outcome evaluation up to two months after imaging.
CONDITIONS
Brief Title
18F-N230A PET/CT Imaging of Nectin-4 Expression in Renal Tumors
Research Team
J
Jianhua Zhang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here